Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan

Ruth Gross-Isseroff; Rivka Cohen; Yehuda Sasson; Hillary Voet; Joseph Zohar

doi:10.1159/000079970

Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan

Ruth Gross-Isseroff^*, Rivka Cohen, Yehuda Sasson, Hillary Voet, Joseph Zohar

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

We have conducted a pharmacological challenge experiment in 10 medication-free obsessive compulsive (OC) disorder (OCD) patients. We used a placebo-controlled paradigm for m-chlorophenylpiperazine (mCPP) and sumatriptan challenges. Endocrine, physiological and behavioral variables were assessed at baseline and over a 3-hour period after the challenge. Both cortisol and prolactin were significantly elevated in OCD patients following mCPP administration. Both mCPP and sumatriptan caused significant OC symptom exacerbation with the response to sumatriptan being more robust. We conclude that the 5-HT_1Dβ receptor may play a role in the pathophysiology of OCD.

Original language	English
Pages (from-to)	200-205
Number of pages	6
Journal	Neuropsychobiology
Volume	50
Issue number	3
DOIs	https://doi.org/10.1159/000079970
State	Published - 2004
Externally published	Yes

Keywords

5-HT receptor
Obsessive compulsive disorder
Pharmacological challenge
Sumatriptan
m-chlorophenylpiperazine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000079970

Cite this

@article{db84f5e1509c4d52a5595c18677f2888,

title = "Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan",

abstract = "We have conducted a pharmacological challenge experiment in 10 medication-free obsessive compulsive (OC) disorder (OCD) patients. We used a placebo-controlled paradigm for m-chlorophenylpiperazine (mCPP) and sumatriptan challenges. Endocrine, physiological and behavioral variables were assessed at baseline and over a 3-hour period after the challenge. Both cortisol and prolactin were significantly elevated in OCD patients following mCPP administration. Both mCPP and sumatriptan caused significant OC symptom exacerbation with the response to sumatriptan being more robust. We conclude that the 5-HT1Dβ receptor may play a role in the pathophysiology of OCD.",

keywords = "5-HT receptor, Obsessive compulsive disorder, Pharmacological challenge, Sumatriptan, m-chlorophenylpiperazine",

author = "Ruth Gross-Isseroff and Rivka Cohen and Yehuda Sasson and Hillary Voet and Joseph Zohar",

year = "2004",

doi = "10.1159/000079970",

language = "אנגלית",

volume = "50",

pages = "200--205",

journal = "Neuropsychobiology",

issn = "0302-282X",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Serotonergic dissection of obsessive compulsive symptoms

T2 - A challenge study with m-chlorophenylpiperazine and sumatriptan

AU - Gross-Isseroff, Ruth

AU - Cohen, Rivka

AU - Sasson, Yehuda

AU - Voet, Hillary

AU - Zohar, Joseph

PY - 2004

Y1 - 2004

N2 - We have conducted a pharmacological challenge experiment in 10 medication-free obsessive compulsive (OC) disorder (OCD) patients. We used a placebo-controlled paradigm for m-chlorophenylpiperazine (mCPP) and sumatriptan challenges. Endocrine, physiological and behavioral variables were assessed at baseline and over a 3-hour period after the challenge. Both cortisol and prolactin were significantly elevated in OCD patients following mCPP administration. Both mCPP and sumatriptan caused significant OC symptom exacerbation with the response to sumatriptan being more robust. We conclude that the 5-HT1Dβ receptor may play a role in the pathophysiology of OCD.

AB - We have conducted a pharmacological challenge experiment in 10 medication-free obsessive compulsive (OC) disorder (OCD) patients. We used a placebo-controlled paradigm for m-chlorophenylpiperazine (mCPP) and sumatriptan challenges. Endocrine, physiological and behavioral variables were assessed at baseline and over a 3-hour period after the challenge. Both cortisol and prolactin were significantly elevated in OCD patients following mCPP administration. Both mCPP and sumatriptan caused significant OC symptom exacerbation with the response to sumatriptan being more robust. We conclude that the 5-HT1Dβ receptor may play a role in the pathophysiology of OCD.

KW - 5-HT receptor

KW - Obsessive compulsive disorder

KW - Pharmacological challenge

KW - Sumatriptan

KW - m-chlorophenylpiperazine

UR - http://www.scopus.com/inward/record.url?scp=4644346877&partnerID=8YFLogxK

U2 - 10.1159/000079970

DO - 10.1159/000079970

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:4644346877

SN - 0302-282X

VL - 50

SP - 200

EP - 205

JO - Neuropsychobiology

JF - Neuropsychobiology

IS - 3

ER -

Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this